Skip to content

One-step Application of Artificial Dermis

A Study to Observe the Effect of One-step Application of Artificial Dermis on Burn and Plastic Wounds

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05666830
Enrollment
37
Registered
2022-12-28
Start date
2021-01-28
Completion date
2022-09-30
Last updated
2022-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wounds and Injuries

Brief summary

The goal of this observational study is to study the effectiveness of one-step application of Lando® artificial dermal regeneration matrix for burn and plastic wound repair. The main question it aims to answer is: the effectiveness of one-step application of Lando® artificial dermal regeneration matrix, including the take rate of skin graft and the appearance recovery of the wound. Participants will be treated with artificial dermis that perfomed with STSG simultaneously. According to the routine clinical practice, the take rate of split-thickness skin graft at about 2-3 weeks and the appearance recovery of the wound at 3 months and 6 months after the implantation were measured.

Interventions

DEVICELando® artificial dermal regeneration matrix

Participants will be treated with artificial dermis that perfomed with STSG simultaneously.

Sponsors

Nanfang Hospital, Southern Medical University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 70 Years

Inclusion criteria

1. Age ≤ 70 years old. 2. Patients with non-infectious wounds of deep burns, full-thickness traumatic skin defects or plastic surgery that need to be repaired and reconstructed by artificial dermis. 3. Patients who voluntarily participate in this clinical trial and sign the informed consent form. When the subjects are under 18 years old or they have no capacity or limited capacity, they should have the consent and signature of the guardian or legal representative.

Exclusion criteria

1. Patients who need to participate in other clinical researchers within 30 days before or during the period of joining the group. 2. Patients with poor control of diabetes (those with fasting blood glucose ≥ 7.0mmol/L or glycosylated hemoglobin HbA1c ≥ 12% after drug control, transaminase \> 1.5 times and other diabetic complications). 3. Other cases that researchers believe not suitable for the participants of the trial.

Design outcomes

Primary

MeasureTime frameDescription
Take rate of skin graft2~3 weeksThe percentage of the area of survival skin graft assessed by the Investigator.

Secondary

MeasureTime frameDescription
Effective rate of skin grafting2~3 weeksThe rate that the number of cases with excellent or good result divided by the total cases participated. Excellent:take rate of skin graft\>90%; Good:take rate of skin graft between 81% and 90%; Fair:take rate of skin graft between 61% and 80%; Poor:take rate of skin graft\<60%。
Vancouver Scar Scale score of skin grafting site3 monthsVancouver Scar Scale score of skin grafting site after 3 months assessed by the Investigator.
Vancouver Scar Scale score of donor site3 monthsVancouver Scar Scale score of donor site after 3 months assessed by the Investigator.
Percentage of wound contraction3 monthsThe Percentage that the area of skin grafting area divided by the original area.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026